Login
   Home       About Us       Services       Personnel       Contact Us       Website Outline   
  Location: Home / Overstatement of Risks By The Linearized Multistag Monday, September 06, 2010
OVERSTATEMENT OF RISKS BY THE LINEARIZED MULTISTAGE MODEL

 

The linearized multistage models q1* upper-bound potency does not provide the best estimates of the added risks implied by the available data.  The best estimates from the multistage model are its maximum likelihood estimates (that is, the estimates from the fitted multistage model).  As noted earlier, the limited flexibility in the functional form of the multistage model may force even the models maximum likelihood estimates to overstate the added risks at a dose.  Thus, as illustrated in Figure 6, the exaggeration of the added risks in the linearized multistage models upper bounds on risk comes on top of any exaggeration in the maximum likelihood estimates from the fitted multistage model.

 

 >>Figure 6

 

3. Human Health Risk Assessment
3.1      Quantitative Risk Assessment and Statistical Analysis
3.2      Importance of Dose and Dose-Response Relationships
3.3      Misuse of Regulatory Upper-Bound Risk Characterizations
3.4      Risk Characterization Choices and Risk Exaggeration
3.5      A Better Approach to Cancer Risk Characterization
3.6      Overview of Background, Motivation, and Statistical Methods for Margin-of-Exposure Characterizations of Cancer Risks
           3.6.1    Importance of Dose
           3.6.2    Dose-Response Modeling
           3.6.3    Dose-Response Models
           3.6.4    Maximum Likelihood Estimation
           3.6.5    Multistage Model
           3.6.6    Example of Fitted Multistage Model
           3.6.7    Potency
           3.6.8    Linearized Multistage Model
           3.6.9    Overstatement of Risks by the Linearized Multistage Model
           3.6.10  Adverse Impacts of the Variability in the Magnitude of the Bias in the Linearized Multistage Model's Overstatement of Risks
           3.6.11  Non-Responsiveness of the Linearized Multistage Model to Data
           3.6.12  Ranking Relative Risks
           3.6.13  Added Risk versus Extra Risk
           3.6.14  Need for a Better Dose-Response Characterization
           3.6.15  Better Dose-Response Characterization
           3.6.16  Benchmark Doses
           3.6.17  Responsiveness of Benchmark Doses Data Versus the Relative Non-Responsiveness of the Regulatory Upper-Bound Potency Q1* based on the Linearized Multistage Model
           3.6.18  Recommended Dose-Response Characterization
           3.6.19  Margin-of-Exposure Characterizations
           3.6.20  Conclusion
           3.6.21  Figures 1 to 16
3.7      Innovative Risk Assessment
3.8      Components of High-to-Low-Dose Extrapolation and Dose-Response Modeling
3.9      Probabilistic Exposure Assessment
3.10    Aggregate Risk Assessment
3.11    Cumulative Risk Assessment
3.12    Example Activities
Copyright ©2010 Sielken & Associates - Statistical Research and Consulting Privacy Statement | Terms Of Use | Powered by AgniTEK Blaze